The Protein Synthesis Inhibitor Anisomycin Induces Macrophage Apoptosis in Rabbit Atherosclerotic Plaques through p38 Mitogen-Activated Protein Kinase

被引:53
|
作者
Croons, Valerie [1 ]
Martinet, Wim [1 ]
Herman, Arnold G. [1 ]
Timmermans, Jean-Pierre [2 ]
De Meyer, Guido R. Y. [1 ]
机构
[1] Univ Antwerp, Div Pharmacol, B-2610 Antwerp, Belgium
[2] Univ Antwerp, Cell Biol & Histol Lab, B-2610 Antwerp, Belgium
关键词
CAROTID-ARTERY; MAP-KINASES; CYCLOHEXIMIDE; PATHWAYS; EXPRESSION; RIBOSOMES; PUROMYCIN; SIGNAL; CELLS; FATE;
D O I
10.1124/jpet.108.149948
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Because macrophages play a major role in atherosclerotic plaque destabilization, selective removal of macrophages represents a promising approach to stabilize plaques. We showed recently that the protein synthesis inhibitor cycloheximide, in contrast to puromycin, selectively depleted macrophages in rabbit atherosclerotic plaques without affecting smooth muscle cells (SMCs). The mechanism of action of these two translation inhibitors is dissimilar and could account for the differential effects on SMC viability. It is not known whether selective depletion of macrophages is confined to cycloheximide or whether it can also be achieved with translation inhibitors that have a similar mechanism of action. Therefore, in the present study, we investigated the effect of anisomycin, a translation inhibitor with a mechanism of action similar to cycloheximide, on macrophage and SMC viability. In vitro, anisomycin induced apoptosis of macrophages in a concentration-dependent manner, whereas SMCs were only affected at higher concentrations. In vivo, anisomycin selectively decreased the macrophage content of rabbit atherosclerotic plaques through apoptosis. The p38 mitogen-activated protein kinase (MAPK) inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5(4-pyridyl)-1H-imidazole] prevented anisomycin-induced macrophage death, without affecting SMC viability. SB202190 decreased anisomycin-induced p38 MAPK phosphorylation, did not alter c-Jun NH 2-terminal kinase (JNK) phosphorylation, and increased extracellular signal-regulated kinase (ERK) 1/2 phosphorylation. The latter effect was abolished by the mitogenactivated protein kinase kinase 1/2 inhibitor U0126 [1,4-diamino2,3-dicyano-1,4-bis(2-aminophynyltio)butadiene ethanolate], although the prevention of anisomycin-induced macrophage death by SB202190 remained unchanged. The JNK phosphorylation inhibitor SP600125 did not affect anisomycin-induced macrophage or SMC death. In conclusion, anisomycin selectively decreased the macrophage content in rabbit atherosclerotic plaques, indicating that this effect is not confined to cycloheximide. p38 MAPK, but not ERK1/2 or JNK, plays a major role in anisomycin-induced macrophage death.
引用
收藏
页码:856 / 864
页数:9
相关论文
共 50 条
  • [41] Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase
    Kummer, JL
    Rao, PK
    Heidenreich, KA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (33) : 20490 - 20494
  • [42] p38α mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli
    Porras, A
    Zuluaga, S
    Black, E
    Valladares, A
    Alvarez, AM
    Ambrosino, C
    Benito, M
    Nebreda, AR
    MOLECULAR BIOLOGY OF THE CELL, 2004, 15 (02) : 922 - 933
  • [44] A p38α selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss
    Kirkwood, Keith L.
    Li, Fei
    Rogers, Jill E.
    Otremba, Jodie
    Coatney, Derek D.
    Kreider, Jaclynn M.
    D'Silva, Nisha J.
    Chakravarty, Sarvajit
    Dugar, Sundeep
    Higgins, Linda S.
    Protter, Andrew A.
    Medicherla, Satyanarayana
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 320 (01): : 56 - 63
  • [45] Effect of a p38 Mitogen-Activated Protein Kinase Inhibitor on Corneal Endothelial Cell Proliferation
    Nakahara, Makiko
    Okumura, Naoki
    Nakano, Shinichiro
    Koizumi, Noriko
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (10) : 4218 - 4227
  • [46] RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase
    Wadsworth, SA
    Cavender, DE
    Beers, SA
    Lalan, P
    Schafer, PH
    Malloy, EA
    Wu, W
    Fahmy, B
    Olini, GC
    Davis, JE
    Pellegrino-Gensey, JL
    Wachter, MP
    Siekierka, JJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 291 (02): : 680 - 687
  • [47] Antioxidative effect of p38 mitogen-activated protein kinase inhibitor in the kidney of hypertensive rat
    Tojo, A
    Onozato, ML
    Kobayashi, N
    Goto, AG
    Matsuoka, H
    Fujita, T
    JOURNAL OF HYPERTENSION, 2005, 23 (01) : 165 - 174
  • [48] p38 mitogen-activated protein kinase inhibitor suppresses apoptosis in a Fuchs endothelial corneal dystrophy cellular model
    Onishi, Takako
    Okumura, Naoki
    Kusakabe, Ayaka
    Kitahara, Miu
    Hashimoto, Keisuke
    Nakahara, Makiko
    Ueda, Emi
    Tourtas, Theofilos
    Schloetzer-Schrehardt, Ursula
    Kruse, Friedrich E.
    Koizumi, Noriko
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [49] Functional Roles of p38 Mitogen-Activated Protein Kinase in Macrophage-Mediated Inflammatory Responses
    Yang, Yanyan
    Kim, Seung Cheol
    Yu, Tao
    Yi, Young-Su
    Rhee, Man Hee
    Sung, Gi-Ho
    Yoo, Byong Chul
    Cho, Jae Youl
    MEDIATORS OF INFLAMMATION, 2014, 2014
  • [50] Prolonged treatment of primary Hepatocytes with oleate induces insulin resistance through p38 mitogen-activated protein kinase
    Liu, Hui-Yu
    Collins, Qu Fan
    Xiong, Yan
    Moukdar, Fatiha
    Lupo, Edgar G., Jr.
    Liu, Zhenqi
    Cao, Wenhong
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (19) : 14205 - 14212